<DOC>
	<DOCNO>NCT00314782</DOCNO>
	<brief_summary>Two-part , multi-center study design establish maximum tolerate dose ( MTD ) ZD4054 combination docetaxel explore safety , tolerability , pharmacokinetic ( PK ) profile clinical efficacy patient metastatic hormone-refractory prostate cancer ( HRPC )</brief_summary>
	<brief_title>Phase I Study ZD4054 ( Zibotentan ) Docetaxel Patients With Metastatic HRPC</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Provision inform consent Histological cytological confirmation prostate cancer Evidence metastatic disease CT scan , MRI , bone scan Surgically continuously medically castrate LHRH analogue Progressive disease recent therapy Disease progression CT/MRI Bone scan progression : appearance 1 new lesion since last bone scan Rising PSA World health organization ( WHO ) performance status 0 2 Life expectancy 12 week longer Use antihormonal therapy ( include ketoconazole , aminoglutethimide , finasteride antiandrogen therapy ) within 4 week start study treatment , except bicalutamide nilutamide exclude within 6 week start study treatment . Estramustine estrogens , take , stop least 4 week start treatment . Definite suspect personal history family history adverse drug reaction , hypersensitivity drug endothelin antagonist ; history severe hypersensitivity reaction drug formulate polysorbate 80 . Prior cytotoxic chemotherapy metastatic prostate cancer Radiotherapy within 4 week start study therapy Systemic radionuclide therapy ( ie strontium chloride Sr89 , 186Relabeled HEDP , 153SmEDTMP pentasodium ) within 12 week enter study Use potent CYP450 inhibitor ( itraconazole , ritonavir , indinavir , erythromycin , troleandomycin , clarithromycin , diltiazem , verapamil ) within 2 week study entry . Use potent CYP450 inducer ( phenytoin , rifampicin , carbamazepine phenobarbitone , St. John 's Wort ) within 2 week study entry . NOTE : Dexamethasone know inducer CYP2D6 CYP3A4 consider exclusionary purpose study . New neurologic symptom sign consistent acute evolve spinal cord compression confirm magnetic resonance imaging ( MRI ) ( except previously treat stable symptom ) . History past current epilepsy , epilepsy syndrome , seizure disorder History Migraine chronic headache Symptomatic central nervous system ( CNS ) metastases Absolute Neutrophil Count ( ANC ) &lt; 1.5 x 109/L ( 1,5000/mm3 ) Platelet count &lt; 100 x 109/L ( 100,000/mm3 ) Serum bilirubin great upper limit normal ( ULN ) Alanine amino transferase ( ALT ) aspartate amino transferase ( AST ) great 1.5 time upper limit normal ( ULN ) Creatinine clearance &lt; 50 mL/min QT interval correct heart rate Barrett Formula ( QTc ) &gt; 470 msec screen New York Heart Association ( NYHA ) class IIIV Heart Disease Myocardial infarction ( heart attack ) within past 3 month CTCAE grade â‰¥2 Peripheral Neuropathy Treatment nonapproved investigational drug within 30 day study entry Evidence significant clinical symptom , abnormal laboratory finding recent surgery patient recover make undesirable patient participate study opinion investigator ( ) Involvement plan conduct study Previous treatment present study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>metastatic hormone-refractory prostate cancer ( HRPC )</keyword>
</DOC>